[CYD tetravalent dengue vaccine]

Oubiña M, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001422
Original Title: Vacuna tetravalente CYD-TDV contra el dengue
Authors' recomendations: CONCLUSIONS High-quality evidence shows that the CYD tetravalent dengue vaccine (CYD-TDV) is effective in preventing the symptomatic disease, when comparing its incidence on vaccinated versus non-vaccinated individuals. The effectiveness analysis by subgroups shows that it is higher than in those patients who have become previously and naturally sensitized. The World Health Organization (WHO) recommends its administration in populations showing a seroprevalence higher than 70%. In those populations with a 50-70% seroprevalence, the WHO reports that its use would also be acceptable but the program impact would be lower. It does not recommend its administration to populations with a seroprevalence lower than 50%. There is no information available on its prevalence in Argentina, but it is estimated it would be low based on incidence studies. No health technology assessments or coverage policies were found in Latin America.
Project Status: Completed
Year Published: 2017
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Dengue
  • Dengue Vaccines
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.